Funding Information: This research was funded by the Champalimaud Foundation; by the Fundação para a Ciência e Tecnologia—FCT (Research Grant PTDC/MEC-HEM/30315/2017). Publisher Copyright: © 2022 by the authors.; Multiple myeloma (MM) is the second deadliest hematological cancer. Despite the enormous innovation on MM treatment in the last decades, still 48% of patients die within 5 years after diagnosis. MM dia...
Funding Information: This work was supported by Fundação para a Ciência e a Tecnologia (FCT), research grant number PTDC/MED-ONC/1215/2021/PT. Funding Information: The authors thank FCT and the Champalimaud Foundation for funding. Publisher Copyright: © 2022 by the authors.; Despite the wide variety of existing therapies, multiple myeloma (MM) remains a disease with dismal prognosis. Choosing the right treatmen...
Funding Information: This research was funded by the Champalimaud Foundation; by the Fundação para a Ciência e Tecnologia – FCT (Research Grant PTDC/MEC-HEM/30315/2017) and by Sociedade Portuguesa de Hematologia -SPH (Initiation to Investigation Grant 2018).; Multiple myeloma (MM) is a hematological malignancy of clonal antibody–secreting plasma cells (PCs). MM diagnosis and risk stratification rely on bone mar...
Funding Information: This work was supported by Portuguese national funds, through FCT—Fundação para a Ciência e Tecnologia—in the context of the projects PDTC/MEC-HEM/30315/2017 and PCDC/MED-ONC/1215/2021, and by GILEAD GÉNESE (project PGG/058/2019). RL received a fellowship funded by FCT (2020.4875.BD). This work was also supported by the research infrastructure CONGENTO, co-financed by Lisboa Regional Operat...